ADC Therapeutics SA
ADCT
查看详细走势图
4.010USD
+0.095+2.43%
收盘 02/06, 16:00（美东）报价延迟15分钟
451.63M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.43%
5天
+11.08%
1月
+9.86%
6月
+51.89%
今年开始到现在
+13.60%
1年
+165.56%
查看详细走势图
TradingKey ADC Therapeutics SA股票评分
单位: USD 更新时间: 2026-02-06操作建议
ADC Therapeutics SA当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名54/392位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价8.00。中期看，股价处于平稳状态。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
ADC Therapeutics SA评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
ADC Therapeutics SA亮点
亮点风险
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
业绩增长期
公司处于发展阶段，最新年度总收入70.84M美元
估值低估
公司最新PE估值-2.82，处于3年历史低位
机构减仓
最新机构持股72.94M股，环比减少0.00%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值7.21K
分析师目标
根据
6
位分析师
强力买入
评级
8.000
目标均价
+95.60%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
ADC Therapeutics SA新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
ADC Therapeutics SA简介
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
公司代码ADCT
公司ADC Therapeutics SA
CEOMallik (Ameet)
网址https://adctherapeutics.com/
相关品种
